Influenza A Virus, H5N1 Subtype Infections – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Influenza A Virus, H5N1 Subtype Infections – Pipeline Review, H2 2016’, provides an overview of the Influenza A Virus, H5N1 Subtype Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Influenza A Virus, H5N1 Subtype Infections , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Influenza A Virus, H5N1 Subtype Infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Influenza A Virus, H5N1 Subtype Infections

The report reviews pipeline therapeutics for Influenza A Virus, H5N1 Subtype Infections by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Influenza A Virus, H5N1 Subtype Infections therapeutics and enlists all their major and minor projects

The report assesses Influenza A Virus, H5N1 Subtype Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Influenza A Virus, H5N1 Subtype Infections

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Influenza A Virus, H5N1 Subtype Infections

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Influenza A Virus, H5N1 Subtype Infections pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Akshaya Bio Inc

Altimmune Inc

Antigen Express Inc

Aphios Corp

BioDiem Ltd

BiondVax Pharmaceuticals Ltd

CEL-SCI Corp

Cocrystal Pharma Inc

Emergent BioSolutions Inc

Gemmus Pharma Inc

GlaxoSmithKline Plc

Hemispherx Biopharma Inc

iBio Inc

Inovio Pharmaceuticals Inc

Johnson & Johnson

Kineta Inc

Lakewood-Amedex Inc

Medicago Inc

Medigen Vaccine Biologics Corp.

Microbiotix Inc

NanoBio Corp

Nanotherapeutics Inc

NanoViricides Inc

NewLink Genetics Corp

OPKO Health Inc

PaxVax Inc

PeptiDream Inc

Protein Sciences Corp

Shionogi & Co Ltd

Takeda Pharmaceutical Company Ltd

TechnoVax Inc

TGV-Laboratories

Vaxart Inc

Vaxine Pty Ltd

VaxInnate Corp

Visterra Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Influenza A Virus, H5N1 Subtype Infections Overview 9

Therapeutics Development 10

Pipeline Products for Influenza A Virus, H5N1 Subtype Infections - Overview 10

Pipeline Products for Influenza A Virus, H5N1 Subtype Infections - Comparative Analysis 11

Influenza A Virus, H5N1 Subtype Infections - Therapeutics under Development by Companies 12

Influenza A Virus, H5N1 Subtype Infections - Therapeutics under Investigation by Universities/Institutes 15

Influenza A Virus, H5N1 Subtype Infections - Pipeline Products Glance 16

Late Stage Products 16

Clinical Stage Products 17

Early Stage Products 18

Influenza A Virus, H5N1 Subtype Infections - Products under Development by Companies 19

Influenza A Virus, H5N1 Subtype Infections - Products under Investigation by Universities/Institutes 23

Influenza A Virus, H5N1 Subtype Infections - Companies Involved in Therapeutics Development 24

Akshaya Bio Inc 24

Altimmune Inc 25

Antigen Express Inc 26

Aphios Corp 27

BioDiem Ltd 28

BiondVax Pharmaceuticals Ltd 29

CEL-SCI Corp 30

Cocrystal Pharma Inc 31

Emergent BioSolutions Inc 32

Gemmus Pharma Inc 33

GlaxoSmithKline Plc 34

Hemispherx Biopharma Inc 35

iBio Inc 36

Inovio Pharmaceuticals Inc 37

Johnson & Johnson 38

Kineta Inc 39

Lakewood-Amedex Inc 40

Medicago Inc 41

Medigen Vaccine Biologics Corp. 42

Microbiotix Inc 43

NanoBio Corp 44

Nanotherapeutics Inc 45

NanoViricides Inc 46

NewLink Genetics Corp 47

OPKO Health Inc 48

PaxVax Inc 49

PeptiDream Inc 50

Protein Sciences Corp 51

Shionogi & Co Ltd 52

Takeda Pharmaceutical Company Ltd 53

TechnoVax Inc 54

TGV-Laboratories 55

Vaxart Inc 56

Vaxine Pty Ltd 57

VaxInnate Corp 58

Visterra Inc 59

Influenza A Virus, H5N1 Subtype Infections - Therapeutics Assessment 60

Assessment by Monotherapy Products 60

Assessment by Combination Products 61

Assessment by Target 62

Assessment by Mechanism of Action 64

Assessment by Route of Administration 66

Assessment by Molecule Type 68

Drug Profiles 70

A-06 - Drug Profile 70

AE-443p - Drug Profile 71

Alferon LDO - Drug Profile 72

APP-0205 - Drug Profile 74

APP-309 - Drug Profile 75

AT-301 - Drug Profile 76

CEL-1000 - Drug Profile 77

CHOS-05 - Drug Profile 79

DPC-005 - Drug Profile 80

FBF-001 - Drug Profile 81

Gamma-Flu - Drug Profile 82

GP-1001 - Drug Profile 83

GP-1002 - Drug Profile 84

GP-1681 - Drug Profile 85

GREFLU/VIE - Drug Profile 87

HAI-05 - Drug Profile 88

HB-36.6 - Drug Profile 89

Influ-nRNA - Drug Profile 90

influenza [strain A/H5N1] (split virion) vaccine - Drug Profile 91

influenza [strain A/H5N1] (virus like particle) vaccine 2 - Drug Profile 92

influenza [strain A/H5N1] vaccine - Drug Profile 95

influenza [strain A/H5N1] vaccine - Drug Profile 96

influenza [strain A/H5N1] vaccine - Drug Profile 97

influenza [strain A/H5N1] vaccine - Drug Profile 99

influenza [strain A/H5N1] vaccine - Drug Profile 100

influenza [strain A/H5N1] vaccine - Drug Profile 101

influenza [strain A/H5N1] vaccine - Drug Profile 102

influenza [strain A/H5N1] vaccine - Drug Profile 103

influenza [strain A/H5N1] vaccine - Drug Profile 104

influenza [strain A/H5N1] vaccine 2 - Drug Profile 105

influenza [strains A/H1N1 + A/H3N2 + A/H5N1] (virus like particle) vaccine - Drug Profile 106

influenza [strains A/H1N1 + A/H3N2 + A/H5N1] vaccine - Drug Profile 107

influenza [strains A/H5N1 + A/H1N1] vaccine - Drug Profile 108

influenza [strains A/H5N1 + A/H7N2 + A/H9N2] (virus like particle) vaccine - Drug Profile 109

influenza vaccine - Drug Profile 110

INO-3510 - Drug Profile 111

JNJ-872 - Drug Profile 113

KD-295 - Drug Profile 115

KIN-1148 - Drug Profile 116

Lalistat - Drug Profile 117

M-001 - Drug Profile 118

MBX-2329 - Drug Profile 123

MBX-2546 - Drug Profile 124

Monoclonal Antibodies to Inhibit Hemagglutinin for Avian Infection and Swine Flu Infection - Drug Profile 125

MV-4 - Drug Profile 126

MVAH-5HA - Drug Profile 127

Nasovax - Drug Profile 128

NVINF-1 - Drug Profile 130

NVINF-2 - Drug Profile 134

OrniFlu - Drug Profile 137

PanBlok - Drug Profile 138

PD-001 - Drug Profile 141

PNSIA-28 - Drug Profile 142

PNSIA-49 - Drug Profile 143

PXVX-0103 - Drug Profile 144

rintatolimod - Drug Profile 145

S-033188 - Drug Profile 154

Small Molecules for Influenza A Virus H1N1 and H5N1 Infections - Drug Profile 156

Small Molecules to Activate Sirtuin for Influenza - Drug Profile 157

Small Molecules to Inhibit PB2 for Influenza - Drug Profile 158

Synthetic Peptides for Influenza, HSV and HIV Infections - Drug Profile 159

Synthetic Peptides for Viral Infections - Drug Profile 160

TVX-003 - Drug Profile 161

VAX-161C - Drug Profile 162

VGX-3400X - Drug Profile 163

VH-244 - Drug Profile 164

VIS-410 - Drug Profile 165

Influenza A Virus, H5N1 Subtype Infections - Dormant Projects 168

Influenza A Virus, H5N1 Subtype Infections - Discontinued Products 174

Influenza A Virus, H5N1 Subtype Infections - Product Development Milestones 175

Featured News & Press Releases 175

Appendix 185

Methodology 185

Coverage 185

Secondary Research 185

Primary Research 185

Expert Panel Validation 185

Contact Us 185

Disclaimer 186

List of Tables

List of Tables

Number of Products under Development for Influenza A Virus, H5N1 Subtype Infections, H2 2016 15

Number of Products under Development for Influenza A Virus, H5N1 Subtype Infections – Comparative Analysis, H2 2016 16

Number of Products under Development by Companies, H2 2016 17

Number of Products under Development by Companies, H2 2016 (Contd..1) 18

Number of Products under Development by Companies, H2 2016 (Contd..2) 19

Number of Products under Investigation by Universities/Institutes, H2 2016 20

Comparative Analysis by Late Stage Development, H2 2016 21

Comparative Analysis by Clinical Stage Development, H2 2016 22

Comparative Analysis by Early Stage Development, H2 2016 23

Products under Development by Companies, H2 2016 24

Products under Development by Companies, H2 2016 (Contd..1) 25

Products under Development by Companies, H2 2016 (Contd..2) 26

Products under Development by Companies, H2 2016 (Contd..3) 27

Products under Investigation by Universities/Institutes, H2 2016 28

Influenza A Virus, H5N1 Subtype Infections – Pipeline by Akshaya Bio Inc, H2 2016 29

Influenza A Virus, H5N1 Subtype Infections – Pipeline by Altimmune Inc, H2 2016 30

Influenza A Virus, H5N1 Subtype Infections – Pipeline by Antigen Express Inc, H2 2016 31

Influenza A Virus, H5N1 Subtype Infections – Pipeline by Aphios Corp, H2 2016 32

Influenza A Virus, H5N1 Subtype Infections – Pipeline by BioDiem Ltd, H2 2016 33

Influenza A Virus, H5N1 Subtype Infections – Pipeline by BiondVax Pharmaceuticals Ltd, H2 2016 34

Influenza A Virus, H5N1 Subtype Infections – Pipeline by CEL-SCI Corp, H2 2016 35

Influenza A Virus, H5N1 Subtype Infections – Pipeline by Cocrystal Pharma Inc, H2 2016 36

Influenza A Virus, H5N1 Subtype Infections – Pipeline by Emergent BioSolutions Inc, H2 2016 37

Influenza A Virus, H5N1 Subtype Infections – Pipeline by Gemmus Pharma Inc, H2 2016 38

Influenza A Virus, H5N1 Subtype Infections – Pipeline by GlaxoSmithKline Plc, H2 2016 39

Influenza A Virus, H5N1 Subtype Infections – Pipeline by Hemispherx Biopharma Inc, H2 2016 40

Influenza A Virus, H5N1 Subtype Infections – Pipeline by iBio Inc, H2 2016 41

Influenza A Virus, H5N1 Subtype Infections – Pipeline by Inovio Pharmaceuticals Inc, H2 2016 42

Influenza A Virus, H5N1 Subtype Infections – Pipeline by Johnson & Johnson, H2 2016 43

Influenza A Virus, H5N1 Subtype Infections – Pipeline by Kineta Inc, H2 2016 44

Influenza A Virus, H5N1 Subtype Infections – Pipeline by Lakewood-Amedex Inc, H2 2016 45

Influenza A Virus, H5N1 Subtype Infections – Pipeline by Medicago Inc, H2 2016 46

Influenza A Virus, H5N1 Subtype Infections – Pipeline by Medigen Vaccine Biologics Corp., H2 2016 47

Influenza A Virus, H5N1 Subtype Infections – Pipeline by Microbiotix Inc, H2 2016 48

Influenza A Virus, H5N1 Subtype Infections – Pipeline by NanoBio Corp, H2 2016 49

Influenza A Virus, H5N1 Subtype Infections – Pipeline by Nanotherapeutics Inc, H2 2016 50

Influenza A Virus, H5N1 Subtype Infections – Pipeline by NanoViricides Inc, H2 2016 51

Influenza A Virus, H5N1 Subtype Infections – Pipeline by NewLink Genetics Corp, H2 2016 52

Influenza A Virus, H5N1 Subtype Infections – Pipeline by OPKO Health Inc, H2 2016 53

Influenza A Virus, H5N1 Subtype Infections – Pipeline by PaxVax Inc, H2 2016 54

Influenza A Virus, H5N1 Subtype Infections – Pipeline by PeptiDream Inc, H2 2016 55

Influenza A Virus, H5N1 Subtype Infections – Pipeline by Protein Sciences Corp, H2 2016 56

Influenza A Virus, H5N1 Subtype Infections – Pipeline by Shionogi & Co Ltd, H2 2016 57

Influenza A Virus, H5N1 Subtype Infections – Pipeline by Takeda Pharmaceutical Company Ltd, H2 2016 58

Influenza A Virus, H5N1 Subtype Infections – Pipeline by TechnoVax Inc, H2 2016 59

Influenza A Virus, H5N1 Subtype Infections – Pipeline by TGV-Laboratories, H2 2016 60

Influenza A Virus, H5N1 Subtype Infections – Pipeline by Vaxart Inc, H2 2016 61

Influenza A Virus, H5N1 Subtype Infections – Pipeline by Vaxine Pty Ltd, H2 2016 62

Influenza A Virus, H5N1 Subtype Infections – Pipeline by VaxInnate Corp, H2 2016 63

Influenza A Virus, H5N1 Subtype Infections – Pipeline by Visterra Inc, H2 2016 64

Assessment by Monotherapy Products, H2 2016 65

Assessment by Combination Products, H2 2016 66

Number of Products by Stage and Target, H2 2016 68

Number of Products by Stage and Mechanism of Action, H2 2016 70

Number of Products by Stage and Route of Administration, H2 2016 72

Number of Products by Stage and Molecule Type, H2 2016 74

Influenza A Virus, H5N1 Subtype Infections – Dormant Projects, H2 2016 173

Influenza A Virus, H5N1 Subtype Infections – Dormant Projects (Contd..1), H2 2016 174

Influenza A Virus, H5N1 Subtype Infections – Dormant Projects (Contd..2), H2 2016 175

Influenza A Virus, H5N1 Subtype Infections – Dormant Projects (Contd..3), H2 2016 176

Influenza A Virus, H5N1 Subtype Infections – Dormant Projects (Contd..4), H2 2016 177

Influenza A Virus, H5N1 Subtype Infections – Dormant Projects (Contd..5), H2 2016 178

Influenza A Virus, H5N1 Subtype Infections – Discontinued Products, H2 2016 179

List of Figures

List of Figures

Number of Products under Development for Influenza A Virus, H5N1 Subtype Infections, H2 2016 15

Number of Products under Development for Influenza A Virus, H5N1 Subtype Infections – Comparative Analysis, H2 2016 16

Number of Products under Development by Companies, H2 2016 17

Number of Products under Investigation by Universities/Institutes, H2 2016 20

Comparative Analysis by Clinical Stage Development, H2 2016 22

Comparative Analysis by Early Stage Products, H2 2016 23

Assessment by Monotherapy Products, H2 2016 65

Number of Products by Top 10 Targets, H2 2016 67

Number of Products by Stage and Top 10 Targets, H2 2016 67

Number of Products by Top 10 Mechanism of Actions, H2 2016 69

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 69

Number of Products by Routes of Administration, H2 2016 71

Number of Products by Stage and Routes of Administration, H2 2016 71

Number of Products by Top 10 Molecule Types, H2 2016 73

Number of Products by Stage and Top 10 Molecule Types, H2 2016 73

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports